We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
Read MoreHide Full Article
Key Takeaways
AstraZeneca gained EU approval for Imfinzi to treat muscle-invasive bladder cancer in adults.
Imfinzi showed a 32% reduced risk of disease progression or death in the NIAGARA phase III study.
Imfinzi sales rose 16% in Q1 2025 to $1.26B, driven by lung and liver cancer treatment demand.
AstraZeneca (AZN - Free Report) announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a bladder cancer indication in the European Union (EU).
The regulatory body in Europe has now approved Imfinzi in combination with gemcitabine and cisplatin as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC), followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy in adult patients.
Imfinzi EU Nod Based on AZN's NIAGARA Study Data
The latest approval was based on data from the phase III NIAGARA study.
Data from the study showed that treatment with an Imfinzi-based perioperative regimen led to a 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus the comparator arm.
The study also demonstrated a 25% reduction in the risk of death in patients treated with the Imfinzi-based perioperative regimen versus the comparator arm.
The EU approval was expected, as the European Medicines Agency’s Committee for Medicinal Products for Human Use had rendered a positive opinion recommending approval of Imfinzi for the given indication in May.
Regulatory applications seeking approval for Imfinzi in MIBC are under review in Japan and several other countries.
Year to date, shares of AstraZeneca have risen 6% against the industry’s decline of 1.4%.
Image Source: Zacks Investment Research
Imfinzi: a Key Revenue Driver for AZN
Imfinzi is the global standard of care in the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy.
Imfinzi, either as a monotherapy or in combination with chemotherapy, is presently approved for stage III NSCLC, extensive-stage small cell lung cancer, locally advanced or metastatic biliary tract cancer and endometrial cancer that is mismatch repair deficient, and in combination with Imjudo in unresectable hepatocellular carcinoma in some countries. The drug was also recently approved for limited-stage small cell lung cancer in the United States and the EU.
Several other label expansion studies on Imfinzi are currently underway, targeting other cancer indications.
Imfinzi remains a key revenue driver for AstraZeneca’s oncology portfolio. In the first quarter of 2025, Imfinzi generated sales of $1.26 billion, up 16% year-over-year, driven by demand growth in lung and liver cancer indications.
AZN's Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.64 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.85 to $3.13. Year to date, shares of EXEL have rallied 38.6%.
EXEL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 48.60%.
In the past 60 days, estimates for Spero Therapeutics’ loss per share have narrowed from $2.32 to $1.43 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.98 to $1.15. Year to date, shares of SPRO have surged 182.6%.
SPRO’s earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, the average surprise being 8.29%.
In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have risen from 48 cents to 51 cents. Year to date, shares of PBYI have gained 17.4%.
PBYI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 171.43%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
Key Takeaways
AstraZeneca (AZN - Free Report) announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a bladder cancer indication in the European Union (EU).
The regulatory body in Europe has now approved Imfinzi in combination with gemcitabine and cisplatin as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC), followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy in adult patients.
Imfinzi EU Nod Based on AZN's NIAGARA Study Data
The latest approval was based on data from the phase III NIAGARA study.
Data from the study showed that treatment with an Imfinzi-based perioperative regimen led to a 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus the comparator arm.
The study also demonstrated a 25% reduction in the risk of death in patients treated with the Imfinzi-based perioperative regimen versus the comparator arm.
The EU approval was expected, as the European Medicines Agency’s Committee for Medicinal Products for Human Use had rendered a positive opinion recommending approval of Imfinzi for the given indication in May.
The FDA approved Imfinzi for a similar indication based on data from the NIAGARA phase III study in March.
Regulatory applications seeking approval for Imfinzi in MIBC are under review in Japan and several other countries.
Year to date, shares of AstraZeneca have risen 6% against the industry’s decline of 1.4%.
Image Source: Zacks Investment Research
Imfinzi: a Key Revenue Driver for AZN
Imfinzi is the global standard of care in the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy.
Imfinzi, either as a monotherapy or in combination with chemotherapy, is presently approved for stage III NSCLC, extensive-stage small cell lung cancer, locally advanced or metastatic biliary tract cancer and endometrial cancer that is mismatch repair deficient, and in combination with Imjudo in unresectable hepatocellular carcinoma in some countries. The drug was also recently approved for limited-stage small cell lung cancer in the United States and the EU.
Several other label expansion studies on Imfinzi are currently underway, targeting other cancer indications.
Imfinzi remains a key revenue driver for AstraZeneca’s oncology portfolio. In the first quarter of 2025, Imfinzi generated sales of $1.26 billion, up 16% year-over-year, driven by demand growth in lung and liver cancer indications.
AZN's Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Exelixis (EXEL - Free Report) , Spero Therapeutics (SPRO - Free Report) and Puma Biotechnology (PBYI - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.64 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.85 to $3.13. Year to date, shares of EXEL have rallied 38.6%.
EXEL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 48.60%.
In the past 60 days, estimates for Spero Therapeutics’ loss per share have narrowed from $2.32 to $1.43 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.98 to $1.15. Year to date, shares of SPRO have surged 182.6%.
SPRO’s earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, the average surprise being 8.29%.
In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have risen from 48 cents to 51 cents. Year to date, shares of PBYI have gained 17.4%.
PBYI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 171.43%.